Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Ultragenyx Pharmaceutical (NASDAQ: RARE) announced the grant of 44,805 restricted stock units (RSUs) to 20 newly hired non-executive officers. The compensation committee approved these awards under the Ultragenyx Employment Inducement Plan, with a grant date of May 16, 2025. The RSUs were granted as employment inducements in compliance with Nasdaq Listing Rule 5635(c)(4). The vesting schedule spans four years, with 25% of shares vesting annually on the grant date anniversary, contingent on continuous employment.

News Market Reaction

-5.19%

1 alert

-5.19% News Effect

On the day this news was published, RARE declined 5.19%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

NOVATO, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 44,805 restricted stock units of the company’s common stock to 20 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company’s board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of May 16, 2025, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).

The restricted stock units vest over four years, with 25% of the underlying shares vesting on each anniversary of the grant date, subject to the employee being continuously employed by the company as of such vesting dates.

About Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultrarare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.

The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.

For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.

Contact Ultragenyx
Investors & Media
Joshua Higa
(415) 475-6370

FAQ

What is the vesting schedule for RARE's May 2025 RSU grants?

The RSUs vest over 4 years, with 25% of the underlying shares vesting on each anniversary of the May 16, 2025 grant date, subject to continuous employment.

How many restricted stock units did Ultragenyx (RARE) grant in May 2025?

Ultragenyx granted 44,805 restricted stock units to 20 newly hired non-executive officers.

Under which plan were Ultragenyx's May 2025 RSUs granted?

The RSUs were granted under the Ultragenyx Employment Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

What is the purpose of RARE's May 2025 stock unit grants?

The restricted stock units were granted as an inducement material to new employees entering into employment with Ultragenyx.